X4 Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
X4 Pharmaceuticals's earnings have been declining at an average annual rate of -11.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 52.4% per year. X4 Pharmaceuticals's return on equity is 18.7%, and it has net margins of 3131.8%.
Key information
-11.1%
Earnings growth rate
43.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -52.4% |
| Return on equity | 18.7% |
| Net Margin | 3,131.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How X4 Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | 18 | 49 | 75 |
| 31 Mar 24 | 0 | -129 | 46 | 70 |
| 31 Dec 23 | 0 | -101 | 36 | 72 |
| 30 Sep 23 | 0 | -111 | 32 | 76 |
| 30 Jun 23 | 0 | -131 | 30 | 71 |
| 31 Mar 23 | 0 | -96 | 27 | 69 |
| 31 Dec 22 | 0 | -96 | 27 | 61 |
| 30 Sep 22 | 0 | -103 | 28 | 54 |
| 30 Jun 22 | 0 | -102 | 27 | 53 |
| 31 Mar 22 | 0 | -100 | 27 | 53 |
| 31 Dec 21 | 0 | -103 | 25 | 51 |
| 30 Sep 21 | 0 | -85 | 23 | 51 |
| 30 Jun 21 | 0 | -82 | 23 | 49 |
| 31 Mar 21 | 0 | -78 | 22 | 45 |
| 31 Dec 20 | 3 | -62 | 21 | 42 |
| 30 Sep 20 | 3 | -55 | 19 | 37 |
| 30 Jun 20 | 3 | -55 | 18 | 34 |
| 31 Mar 20 | 3 | -53 | 18 | 33 |
| 31 Dec 19 | 0 | -53 | 18 | 30 |
| 30 Sep 19 | 0 | -55 | 17 | 28 |
| 30 Jun 19 | 0 | -46 | 15 | 25 |
| 31 Mar 19 | 0 | -40 | 12 | 21 |
| 31 Dec 18 | 0 | -36 | 9 | 20 |
| 30 Sep 18 | 0 | -31 | 7 | 19 |
| 31 Dec 17 | 0 | -25 | 5 | 17 |
Quality Earnings: 48Q has a large one-off gain of $105.0M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 48Q became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 48Q has become profitable over the past 5 years, growing earnings by -11.1% per year.
Accelerating Growth: 48Q has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 48Q has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 48Q's Return on Equity (18.7%) is considered low.